Home/Pipeline/CC-92480 (Mezigdomide)

CC-92480 (Mezigdomide)

Multiple Myeloma

Phase 3ActiveNCT05519085

Key Facts

Indication

Multiple Myeloma

Phase

Phase 3

Status

Active

Company

Bristol Myers Squibb

About Bristol Myers Squibb

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company with a mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company has achieved landmark status through transformative therapies like Opdivo (nivolumab) and Yervoy in immuno-oncology, and maintains a robust pipeline fueled by a strategy of causal human biology and modality matching. BMS's core strategy involves a disciplined R&D framework, strategic business development to bolster its pipeline, and a focus on expanding the reach of its cell therapy and novel oncology assets while navigating near-term patent expirations.

View full company profile

Therapeutic Areas

Oncology Hematology Cardiovascular Disease Immunology Neuroscience

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active
Sequesta™	ID4Pharma	Pre-clinical	Active
Myeloma Consortium	Criterium	Unknown	Active
GPRC5D x CD3 TCE	Integral Molecular	Preclinical	Available for License
RORA-Tscm CAR-T	RORABio	Pre-clinical	Active